Evidence map›Paper›PMID 41590796›Full record

ArticleJournal of functional biomaterials2026

3D Printing of Oxygen-Sensing ECM-Based Skin Graft for Personalized Treatment of Chronic Wounds-A Technological Proof of Concept.

Yehonatan Zur, Rotem Hayam, Nir Almog, Inna Kovrigina, Limor Baruch, Aharon Blank, Marcelle Machluf

Abstract read
In one paragraph

Article in Journal of functional biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yehonatan ZurThe Laboratory for Cancer Drug Delivery & Cell Based Technologies, Faculty of Biotechnology & Food Engineering, Technion-Israel Institute of Technology, Haifa 32000, Israel.ORCID 0009-0003-5169-3468
Rotem HayamThe Laboratory for Cancer Drug Delivery & Cell Based Technologies, Faculty of Biotechnology & Food Engineering, Technion-Israel Institute of Technology, Haifa 32000, Israel.ORCID 0009-0008-9136-0699
Nir AlmogSchulich Faculty of Chemistry, Technion-Israel Institute of Technology, Haifa 32000, Israel.
Inna KovriginaThe Laboratory for Cancer Drug Delivery & Cell Based Technologies, Faculty of Biotechnology & Food Engineering, Technion-Israel Institute of Technology, Haifa 32000, Israel.
Limor BaruchThe Laboratory for Cancer Drug Delivery & Cell Based Technologies, Faculty of Biotechnology & Food Engineering, Technion-Israel Institute of Technology, Haifa 32000, Israel.
Aharon BlankSchulich Faculty of Chemistry, Technion-Israel Institute of Technology, Haifa 32000, Israel.ORCID 0000-0003-4056-8103
Marcelle MachlufThe Laboratory for Cancer Drug Delivery & Cell Based Technologies, Faculty of Biotechnology & Food Engineering, Technion-Israel Institute of Technology, Haifa 32000, Israel.ORCID 0000-0001-5896-963X

Funding

Israel Science Foundation 2283/20
6 · The paper itself

Abstract

Chronic diabetic wounds are often characterized by persistent hypoxia and poor healing outcomes, highlighting the need for regenerative grafts that not only promote tissue repair but also provide insights into the wound microenvironment. In this study, we introduce a novel strategy for diabetic ulcer treatment through the development of a structurally personalized skin graft. The graft is fabricated via 3D bioprinting of natural porcine skin extracellular matrix (psECM) and integrated with microsensors for oxygen monitoring. We established a porcine skin decellularization protocol that efficiently removed cellular components, while preserving the integrity of the ECM, as verified by DNA quantification and scanning electron microscopy. The resulting psECM bioink demonstrated rheological properties suitable for 3D printing, which depended on psECM concentration and exhibited temperature-responsive gelation behavior. Incorporation of LiNC-BuO oxygen microsensors into the bioink enabled real-time, non-invasive oxygen level monitoring within the printed constructs. Both in vitro and in vivo studies confirmed the cytocompatibility and low immunogenicity of the psECM-based grafts with embedded microsensors. Moreover, the 3D bioprinting technology enabled the manufacturing of grafts tailored to match individual wound geometries. The technological proof of concept presented herein for this multifunctional platform, which integrates the regenerative benefits of ECM scaffolds with advanced biosensing capabilities, represents a promising approach for enhancing future therapeutic outcomes in the management of diabetic ulcers.

Indexed as

3D bioprintingadditive manufacturingelectron spin resonance (ESR)extracellular matrix (ECM)oxygen sensorskin grafttissue engineering

Identifiers

PMID41590796
PMCPMC12842197

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.